PepGen Appoints New Chief Business Officer with 160,000 Stock Options Grant
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 09 2025
0mins
Source: Newsfilter
- Executive Appointment: PepGen Inc. appointed Joseph Vittiglio as Chief Business and Legal Officer, granting him 160,000 non-qualified stock options under the 2024 Inducement Plan, with an exercise price of $5.59 per share, reflecting the company's commitment to strengthening its executive team.
- Stock Option Structure: The stock options have a ten-year term and are scheduled to vest over four years, with 25% vesting on the one-year anniversary of Vittiglio's employment and the remainder vesting in equal monthly installments, aimed at incentivizing his long-term service to the company.
- Plan Background: This grant is made under PepGen's 2024 Inducement Plan, adopted by the Board in August 2024, in accordance with Nasdaq Listing Rule 5635(c)(4), indicating the company's strategic intent to attract top talent.
- Company Vision: PepGen is focused on advancing next-generation oligonucleotide therapies to transform the treatment of severe neuromuscular and neurological diseases, and Vittiglio's addition is expected to contribute significantly to achieving this vision.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PEPG?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PEPG
Wall Street analysts forecast PEPG stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PEPG is 11.50 USD with a low forecast of 3.00 USD and a high forecast of 20.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
1 Buy
0 Hold
1 Sell
Hold
Current: 5.220
Low
3.00
Averages
11.50
High
20.00
Current: 5.220
Low
3.00
Averages
11.50
High
20.00
About PEPG
PepGen Inc. is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies. The Company’s Enhanced Delivery Oligonucleotide (EDO) platform leverages cell-penetrating peptides to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake and nuclear delivery. Using these EDO peptides, the Company is generating a pipeline of oligonucleotide therapeutic candidates designed to target the root cause of serious diseases. It is focused on addressing the underlying cause of Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1), which have high unmet need. Its pipeline consists of two clinical stage programs, PGN-EDO51 for DMD patients who are amenable to an exon 51-skipping approach and PGN-EDODM1 for DM1 patients, and several additional preclinical stage programs. Its product candidates also include PGN-EDO53, PGN-EDO45 and PGN-EDO44.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
PepGen Appoints New Chief Business Officer with 160,000 Stock Options Grant
- Executive Appointment: PepGen Inc. appointed Joseph Vittiglio as Chief Business and Legal Officer, granting him 160,000 non-qualified stock options under the 2024 Inducement Plan, with an exercise price of $5.59 per share, reflecting the company's commitment to strengthening its executive team.
- Stock Option Structure: The stock options have a ten-year term and are scheduled to vest over four years, with 25% vesting on the one-year anniversary of Vittiglio's employment and the remainder vesting in equal monthly installments, aimed at incentivizing his long-term service to the company.
- Plan Background: This grant is made under PepGen's 2024 Inducement Plan, adopted by the Board in August 2024, in accordance with Nasdaq Listing Rule 5635(c)(4), indicating the company's strategic intent to attract top talent.
- Company Vision: PepGen is focused on advancing next-generation oligonucleotide therapies to transform the treatment of severe neuromuscular and neurological diseases, and Vittiglio's addition is expected to contribute significantly to achieving this vision.
Continue Reading
Meihua International Medical Technologies, Fly-E Group, and Other Major Stocks Decline in Pre-Market Trading on Monday
U.S. Stock Futures: U.S. stock futures showed mixed results, with Dow futures down approximately 0.1% on Monday morning.
Meihua International Medical Technologies: Shares of Meihua International Medical Technologies fell 32.9% in pre-market trading after the announcement of its delisting from Nasdaq.
Other Notable Stock Movements: Several other stocks experienced significant declines in pre-market trading, including SMX down 17.2%, Gulf Resources down 16.1%, and Wheeler Real Estate down 16.1%.
Market Reactions: The market saw various stocks decline after previous gains, with Fly-E Group and Ecarx Holdings also reporting notable drops due to regulatory issues and market fluctuations.
Continue Reading